Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Inclusion Criteria:

• Non-squamous NSCLC, not amenable to treatment in curative intent.

• Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).

• Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib,lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the mostrecent line of therapy in an adjuvant, locally advanced, or metastatic treatmentsetting.

• Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatinor carboplatin in combination with pemetrexed).

Exclusion criteria:

• Inadequate organ function and/or bone marrow reserve.

• Leptomeningeal metastases or spinal cord compression.

• Poorly controlled systemic medical conditions.

• Other protocol-defined inclusion/exclusion criteria apply.